Abstract
Chromogranin A (ChgA) is an acidic pro-protein found in neuroendocrine organs, pheochromocytoma chromaffin granules, and tumor cells. Proteolytic processing of ChgA gives rise to an array of biologically active peptides such as pancreastatin (PST), vasostatin, WE14, catestatin (CST), and serpinin, which have diverse roles in regulating cardiovascular functions and metabolism, as well as inflammation. Intricate tissue-specific role of ChgA-derived peptide activity in preclinical rodent models of metabolic syndrome reveals complex effects on carbohydrate and lipid metabolism. Indeed, ChgA-derived peptides, PST and CST, play a pivotal role in metabolic syndrome such as obesity, insulin resistance, and diabetes mellitus. Additionally, supplementation of specific peptide in ChgA-KO mice have an opposing effect on physiological functions, such as PST supplementation reduces insulin sensitivity and enhances inflammatory response. In contrast, CST supplementation enhances insulin sensitivity and reduces inflammatory response. In this review, we focus on the tissue-specific role of PST and CST as therapeutic targets in regulating carbohydrate and lipid metabolism, along with the associated risk factors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Ahrén B et al (1996) Pancreastatin modulates glucose-stimulated insulin secretion from the perfused rat pancreas. Acta Physiol Scand 158(1):63–70. https://doi.org/10.1046/j.1365-201X.1996.525291000.x
Alberti KGMM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
Allu PKR et al (2014) Naturally occurring variants of the dysglycemic peptide pancreastatin. J Biol Chem 289(7):4455–4469. https://doi.org/10.1074/jbc.M113.520916
Allu PKR et al (2022) Functional Gly297Ser variant of the physiological dysglycemic peptide pancreastatin is a novel risk factor for cardiometabolic disorders. Diabetes 71(3):538–553. https://doi.org/10.2337/db21-0289
Arden SD et al (1994) The post-translational processing of chromogranin A in the pancreatic islet: involvement of the eukaryote subtilisin PC2. Biochem J 298(3):521–528. https://doi.org/10.1042/bj2980521
Baker RL et al (2016) Cutting edge: nonobese diabetic mice deficient in chromogranin A are protected from autoimmune diabetes. J Immunol 196(1):39–43. https://doi.org/10.4049/jimmunol.1501190
Bandyopadhyay GK, Mahata SK (2017) Chromogranin A regulation of obesity and peripheral insulin sensitivity. Front in Endocrinology. https://doi.org/10.3389/fendo.2017.00020
Bandyopadhyay GK et al (2012) Catestatin (Chromogranin A352–372) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J Biol Chem 287(27):23141–23151. https://doi.org/10.1074/jbc.M111.335877
Bandyopadhyay GK et al (2015) Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance. Diabetes 64(1):104–116. https://doi.org/10.2337/db13-1747
Bartolomucci A et al (2011) The extended granin family: structure, function, and biomedical implications. Endocr Rev 32(6):755–797. https://doi.org/10.1210/er.2010-0027
Biswas N et al (2014) Discovery of a novel target for the dysglycemic chromogranin A fragment pancreastatin: interaction with the chaperone GRP78 to influence metabolism. PLoS ONE 9(1):e84132. https://doi.org/10.1371/journal.pone.0084132
Bryant NJ, Govers R, James DE (2002) Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 3(4):267–277. https://doi.org/10.1038/nrm782
Cai D et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 11(2):183–190. https://doi.org/10.1038/nm1166
Chavez JA, Summers SA (2012) A Ceramide-centric view of insulin resistance. Cell Metab 15(5):585–594. https://doi.org/10.1016/j.cmet.2012.04.002
Cipolletta D et al (2012) PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486(7404):549–553. https://doi.org/10.1038/nature11132
Cohn DV et al (1984) Selective localization of the parathyroid secretory protein-I/adrenal medulla chromogranin A protein family in a wide variety of endocrine cells of the rat*. Endocrinology 114(6):1963–1974. https://doi.org/10.1210/endo-114-6-1963
D’amico MA et al (2014) Biological function and clinical relevance of chromogranin A and derived peptides. Endocr Connect 3(2):R45–R54. https://doi.org/10.1530/EC-14-0027
Dasgupta A et al (2020) Catestatin improves insulin sensitivity by attenuating endoplasmic reticulum stress: in vivo and in silico validation. Comput Struct Biotechnol J 18:464–481. https://doi.org/10.1016/j.csbj.2020.02.005
Delong T et al (2016) Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351(6274):711–714. https://doi.org/10.1126/science.aad2791
Efendić S et al (1987) Pancreastatin and islet hormone release. Proc Natl Acad Sci 84(20):7257–7260. https://doi.org/10.1073/pnas.84.20.7257
Ehrhart M et al (1986) Chromogranin A in the pancreatic islet: cellular and subcellular distribution. J Histochem Cytochem 34(12):1673–1682. https://doi.org/10.1177/34.12.2878021
Eissa N et al (2018) Chromogranin-A and its derived peptides and their pharmacological effects during intestinal inflammation. Biochem Pharmacol 152:315–326. https://doi.org/10.1016/j.bcp.2018.04.009
Fasciotto BH et al (2000) Processing of chromogranin A in the parathyroid: generation of parastatin-related peptides. Peptides 21(9):1389–1401. https://doi.org/10.1016/S0196-9781(00)00283-7
Fazakerley DJ et al (2019) Muscle and adipose tissue insulin resistance: malady without mechanism? J Lipid Res 60(10):1720–1732. https://doi.org/10.1194/jlr.R087510
Feuerer M et al (2009) Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 15(8):930–939. https://doi.org/10.1038/nm.2002
Galic S et al (2011) Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Investig 121(12):4903–4915. https://doi.org/10.1172/JCI58577
Gastaldelli A et al (2000) Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49(8):1367–1373. https://doi.org/10.2337/diabetes.49.8.1367
Gayen JR et al (2009) A novel pathway of insulin sensitivity in chromogranin A null mice. J Biol Chem 284(42):28498–28509. https://doi.org/10.1074/jbc.M109.020636
Gayen JR et al (2010) Role of reactive oxygen species in hyperadrenergic hypertension. Circulation 3(5):414–425. https://doi.org/10.1161/CIRCGENETICS.109.924050
Gioia L et al (2019) Position β57 of I-A g7 controls early anti-insulin responses in NOD mice, linking an MHC susceptibility allele to type 1 diabetes onset. Sci Immunol. https://doi.org/10.1126/sciimmunol.aaw6329
González-Yanes C, Sánchez-Margalet V (2001) Pancreastatin, a chromogranin-A-derived peptide, inhibits insulin-stimulated glycogen synthesis by activating GSK-3 in rat adipocytes. Biochem Biophys Res Commun 289(1):282–287. https://doi.org/10.1006/bbrc.2001.5967
Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5(12):953–964. https://doi.org/10.1038/nri1733
Gupta AP, Syed AA et al (2019) Pancreastatin inhibitor PSTi8 attenuates hyperinsulinemia induced obesity and inflammation mediated insulin resistance via MAPK/NOX3-JNK pathway. Eur J Pharmacol 864:172723. https://doi.org/10.1016/j.ejphar.2019.172723
Gupta AP, Singh P et al (2019) Pancreastatin inhibitor activates AMPK pathway via GRP78 and ameliorates dexamethasone induced fatty liver disease in C57BL/6 mice. Biomed Pharmacother 116:108959. https://doi.org/10.1016/j.biopha.2019.108959
Gupta AP et al (2020) Pancreastatin inhibitor PSTi8 protects the obesity associated skeletal muscle insulin resistance in diet induced streptozotocin-treated diabetic mice. Eur J Pharmacol 881:173204. https://doi.org/10.1016/j.ejphar.2020.173204
Hendy GN et al (2006) Targeted ablation of the chromogranin A (chga) gene: normal neuroendocrine dense-core secretory granules and increased expression of other granins. Mol Endocrinol 20(8):1935–1947. https://doi.org/10.1210/me.2005-0398
Hertelendy ZI, Patel DG, Knittel JJ (1996) Pancreastatin inhibits insulin secretion in RINm5F cells through obstruction of G-protein mediated, calcium-directed exocytosis. Cell Calcium 19(2):125–132. https://doi.org/10.1016/S0143-4160(96)90081-0
Holland WL et al (2011) Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid–induced ceramide biosynthesis in mice. J Clin Investig 121(5):1858–1870. https://doi.org/10.1172/JCI43378
Hossain Z et al (2018) Discovery of pancreastatin inhibitor PSTi8 for the treatment of insulin resistance and diabetes: studies in rodent models of diabetes mellitus. Sci Rep 8(1):8715. https://doi.org/10.1038/s41598-018-27018-8
Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259(5091):87–91. https://doi.org/10.1126/science.7678183
Hotamisligil GS et al (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and Obesity-induced insulin resistance. Science 271(5249):665–670. https://doi.org/10.1126/science.271.5249.665
Huh JY et al (2013) A novel function of adipocytes in lipid antigen presentation to iNKT cells. Mol Cell Biol 33(2):328–339. https://doi.org/10.1128/MCB.00552-12
Iacangelo AL, Eiden LE (1995) Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 58(3):65–88. https://doi.org/10.1016/0167-0115(95)00069-N
Jager J, Aparicio-Vergara M, Aouadi M (2016) Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells. J Intern Med 280(2):209–220. https://doi.org/10.1111/joim.12483
Jonas J-C et al (1999) Chronic hyperglycemia triggers loss of pancreatic β cell differentiation in an animal model of diabetes. J Biol Chem 274(20):14112–14121. https://doi.org/10.1074/jbc.274.20.14112
Ju C, Tacke F (2016) Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol 13(3):316–327. https://doi.org/10.1038/cmi.2015.104
Juul F, Vaidean G, Parekh N (2021) Ultra-processed foods and cardiovascular diseases: potential mechanisms of action. Adv Nutr. https://doi.org/10.1093/advances/nmab049
Katsuura G, Asakawa A, Inui A (2002) Roles of pancreatic polypeptide in regulation of food intake. Peptides 23(2):323–329. https://doi.org/10.1016/S0196-9781(01)00604-0
Kidd LB et al (2008) Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther 326(1):348–353. https://doi.org/10.1124/jpet.108.138891
Kogawa EM et al (2016) Salivary function impairment in type 2 diabetes patients associated with concentration and genetic polymorphisms of chromogranin A. Clin Oral Invest 20(8):2083–2095. https://doi.org/10.1007/s00784-015-1705-z
Kojima M et al (2018) Catestatin prevents macrophage-driven atherosclerosis but not arterial injury-induced neointimal hyperplasia. Thromb Haemost 118(01):182–194. https://doi.org/10.1160/TH17-05-0349
Koshimizu H et al (2010) Reprint of: Chromogranin A: a new proposal for trafficking, processing and induction of granule biogenesis. Regul Pept 165(1):95–101. https://doi.org/10.1016/j.regpep.2010.09.006
Krenkel O, Tacke F (2017) Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 17(5):306–321. https://doi.org/10.1038/nri.2017.11
Li P et al (2015) LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med 21(3):239–247. https://doi.org/10.1038/nm.3800
Li P et al (2016) Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance. Cell 167(4):973-984.e12. https://doi.org/10.1016/j.cell.2016.10.025
Liu T et al (2019) Adipose tissue macrophage-derived exosomal miR-29a regulates obesity-associated insulin resistance. Biochem Biophys Res Commun 515(2):352–358. https://doi.org/10.1016/j.bbrc.2019.05.113
Loh YP et al (2012a) Chromogranin A and derived peptides in health and disease. J Mol Neurosci 48(2):347–356. https://doi.org/10.1007/s12031-012-9728-2
Loh PY et al (2012b) Serpinins: role in granule biogenesis, inhibition of cell death and cardiac function. Curr Med Chem 19(24):4086–4092. https://doi.org/10.2174/092986712802429957
Lukinius A, Stridsberg M, Wilander E (2003) Cellular expression and specific intragranular localization of chromogranin A, chromogranin B, and synaptophysin during ontogeny of pancreatic islet cells: an ultrastructural study. Pancreas 27(1):38–46. https://doi.org/10.1097/00006676-200307000-00006
Lynch L (2014) Adipose invariant natural killer T cells. Immunology 142(3):337–346. https://doi.org/10.1111/imm.12269
Ma H-T, Kato M, Tatemoto K (1996) Effects of pancreastatin and somatostatin on secretagogues-induced rise in intracellular free calcium in single rat pancreatic islet cells. Regul Pept 61(2):143–148. https://doi.org/10.1016/0167-0115(95)00160-3
Mahapatra NR (2008) Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Cardiovasc Res 80(3):330–338. https://doi.org/10.1093/cvr/cvn155
Mahapatra NR et al (2005) Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Investig 115(7):1942–1952. https://doi.org/10.1172/JCI24354
Matsumoto M et al (2007) Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor foxo1 in liver. Cell Metab 6(3):208–216. https://doi.org/10.1016/j.cmet.2007.08.006
Michels AW et al (2017) Islet-derived CD4 T cells targeting proinsulin in human autoimmune diabetes. Diabetes 66(3):722–734. https://doi.org/10.2337/db16-1025
Nakayama M et al (2005) Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435(7039):220–223. https://doi.org/10.1038/nature03523
Nishimura S et al (2009) CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15(8):914–920. https://doi.org/10.1038/nm.1964
O’Connor DT, Burton D, Deftos LJ (1983) Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. Life Sci 33(17):1657–1663. https://doi.org/10.1016/0024-3205(83)90721-X
O’Connor DT et al (2005) Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab 90(9):5414–5425. https://doi.org/10.1210/jc.2005-0408
Orliaguet L, Ejlalmanesh T, Alzaid F (2020) Metabolic and molecular mechanisms of macrophage polarisation and adipose tissue insulin resistance. Int J Mol Sci 21(16):5731. https://doi.org/10.3390/ijms21165731
Pal M, Febbraio MA, Lancaster GI (2016) The roles of c-Jun NH 2-terminal kinases (JNKs) in obesity and insulin resistance. J Physiol 594(2):267–279. https://doi.org/10.1113/JP271457
Portela-Gomes GM et al (2005) Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. Virchows Arch 446(6):604–612. https://doi.org/10.1007/s00428-005-1222-6
Portela-Gomes GM et al (2008) The importance of chromogranin A in the development and function of endocrine pancreas. Regul Pept 151(1–3):19–25. https://doi.org/10.1016/j.regpep.2008.07.005
Rajaram MVS et al (2006) Akt/protein kinase B modulates macrophage inflammatory response to Francisella infection and confers a survival advantage in mice. J Immunol 177(9):6317–6324. https://doi.org/10.4049/jimmunol.177.9.6317
Rangel-Huerta OD, Pastor-Villaescusa B, Gil A (2019) Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics. https://doi.org/10.1007/s11306-019-1553-y
Reza MI, Syed AA, Singh P et al (2021a) Pancreastatin induces hepatic steatosis in type 2 diabetes by impeding mitochondrial functioning. Life Sci 284:119905. https://doi.org/10.1016/j.lfs.2021.119905
Reza MI, Syed AA, Kumariya S et al (2021b) Pancreastatin induces islet amyloid peptide aggregation in the pancreas, liver, and skeletal muscle: an implication for type 2 diabetes. Int J Biol Macromol 182:760–771. https://doi.org/10.1016/j.ijbiomac.2021.04.064
Roep BO, Peakman M (2012) Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med 2(4):a007781–a007781. https://doi.org/10.1101/cshperspect.a007781
Sabio G et al (2009) Prevention of steatosis by hepatic JNK1. Cell Metab 10(6):491–498. https://doi.org/10.1016/j.cmet.2009.09.007
Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148(5):852–871. https://doi.org/10.1016/j.cell.2012.02.017
Sanchez V, Calvo JR, Goberna R (1990) Glycogenolytic effect of pancreastatin in the rat. Biosci Rep 10(1):87–91. https://doi.org/10.1007/BF01116856
Sánchez V et al (1992) Glycogenolytic effect of pancreastatin in isolated rat hepatocytes is mediated by a cyclic-AMP-independent Ca2+-dependent mechanism. Biochem J 284(3):659–662. https://doi.org/10.1042/bj2840659
Sánchez-Margalet V, González-Yanes C (1998) Pancreastatin inhibits insulin action in rat adipocytes. Am J Physiol Endocrinol Metab 275(6):E1055–E1060. https://doi.org/10.1152/ajpendo.1998.275.6.E1055
Sánchez-Margalet V, Calvo J, Goberna R (1992) Glucogenolytic and hyperglycemic effect of 33–49 C-terminal fragment of pancreastatin in the rat in vivo. Horm Metab Res 24(10):455–457. https://doi.org/10.1055/s-2007-1003361
Sano H et al (2003) Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 278(17):14599–14602. https://doi.org/10.1074/jbc.C300063200
Seo JB et al (2018) Knockdown of ANT2 reduces adipocyte hypoxia and improves insulin resistance in obesity. Nat Metab 1(1):86–97. https://doi.org/10.1038/s42255-018-0003-x
Simunovic M et al (2019) Serum catestatin concentrations are decreased in obese children and adolescents. Pediatr Diabetes. https://doi.org/10.1111/pedi.12825
Singh P et al (2020) PSTi8 with metformin ameliorates perimenopause induced steatohepatitis associated ER stress by regulating SIRT-1/SREBP-1c axis. Heliyon 6(12):e05826. https://doi.org/10.1016/j.heliyon.2020.e05826
Singh P et al (2021) Pancreastatin mediated regulation of UCP-1 and energy expenditure in high fructose fed perimenopausal rats. Life Sci 279:119677. https://doi.org/10.1016/j.lfs.2021.119677
Smith GI, Mittendorfer B, Klein S (2019) Metabolically healthy obesity: facts and fantasies. J Clin Investig 129(10):3978–3989. https://doi.org/10.1172/JCI129186
Srivastava N et al (2021) Chromogranin A deficiency confers protection from autoimmune diabetes via multiple mechanisms. Diabetes 70(12):2860–2870. https://doi.org/10.2337/db21-0513
Stadinski BD et al (2010) Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 11(3):225–231. https://doi.org/10.1038/ni.1844
Stettler H et al (2009) Determinants for chromogranin A sorting into the regulated secretory pathway are also sufficient to generate granule-like structures in non-endocrine cells. Biochem J 418(1):81–91. https://doi.org/10.1042/BJ20071382
Stöckli J, Fazakerley DJ, James DE (2011) GLUT4 exocytosis. J Cell Sci 124(24):4147–4159. https://doi.org/10.1242/jcs.097063
Tang K et al (2017) Muscle injury, impaired muscle function and insulin resistance in Chromogranin A-knockout mice. J Endocrinol 232(2):137–153. https://doi.org/10.1530/JOE-16-0370
Tatemoto K et al (1986) Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324(6096):476–478. https://doi.org/10.1038/324476a0
Valicherla GR et al (2019) Pancreastatin inhibitor, PSTi8 ameliorates metabolic health by modulating AKT/GSK-3β and PKCλ/ζ/SREBP1c pathways in high fat diet induced insulin resistance in peri-/post-menopausal rats. Peptides 120:170147. https://doi.org/10.1016/j.peptides.2019.170147
Valicherla GR et al (2020) LC-ESI-MS/MS assay development and validation of a novel antidiabetic peptide PSTi8 in mice plasma using SPE: an application to pharmacokinetics. J Pharma Biomed Anal 180:113074. https://doi.org/10.1016/j.jpba.2019.113074
Valicherla GR et al (2022) Evaluation of the pharmacokinetics of the pancreastatin inhibitor PSTi8 peptide in rats: Integration of in vitro and in vivo findings. Molecules 27(2):339. https://doi.org/10.3390/molecules27020339
Varndell IM et al (1985) Ultrastructural localization of chromogranin: a potential marker for the electron microscopical recognition of endocrine cell secretory granules. Histochem J 17(9):981–992. https://doi.org/10.1007/BF01417947
Weisberg SP et al (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Investig 112(12):1796–1808. https://doi.org/10.1172/JCI19246
Wilson BS, Lloyd Rv (1984) Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Am J Pathol 115(3):458–468
Winer S et al (2009) Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 15(8):921–929. https://doi.org/10.1038/nm.2001
Winer DA et al (2011) B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 17(5):610–617. https://doi.org/10.1038/nm.2353
Wollam J et al (2017) Chromogranin A regulates vesicle storage and mitochondrial dynamics to influence insulin secretion. Cell Tissue Res 368(3):487–501. https://doi.org/10.1007/s00441-017-2580-5
Ying W et al (2017) Adipose tissue B2 cells promote insulin resistance through leukotriene LTB4/LTB4R1 signaling. J Clin Investig 127(3):1019–1030. https://doi.org/10.1172/JCI90350
Ying W et al (2018) Catestatin inhibits obesity-induced macrophage infiltration and inflammation in the liver and suppresses hepatic glucose production, leading to improved insulin sensitivity. Diabetes 67(5):841–848. https://doi.org/10.2337/db17-0788
Yoo SH, Huh YH, Hur YS (2010) Inositol 1,4,5-trisphosphate receptor in chromaffin secretory granules and its relation to chromogranins. Cell Mol Neurobiol 30(8):1155–1161. https://doi.org/10.1007/s10571-010-9564-2
Zhang L-H, Zhang X (2010) Roles of GRP78 in physiology and cancer. J Cell Biochem 110(6):1299–1305. https://doi.org/10.1002/jcb.22679
Acknowledgements
The authors are thankful to the Director, CSIR-CDRI for constant encouragement and support. CDRI communication number 10552.
Author information
Authors and Affiliations
Contributions
RG, AA, RK, SD, SY, JRG collected material, analysed, compiled, prepared graphs/figures and wrote/edited the review manuscript
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that there is no potential conflict of interest.
Additional information
Handling editor: S. Albrecht.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Garg, R., Agarwal, A., Katekar, R. et al. Chromogranin A-derived peptides pancreastatin and catestatin: emerging therapeutic target for diabetes. Amino Acids 55, 549–561 (2023). https://doi.org/10.1007/s00726-023-03252-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-023-03252-x